PUBLICATIONS

Martinecz A, Abel zur Wiesch P. Estimating treatment prolongation for persistent infections. Pathogens and Disease. 2018 Aug 9.

 

Zhang T, Abel S, Abel zur Wiesch P, Sasabe J, Davis BM, Higgins DE, Waldor MK. Deciphering the landscape of host barriers to Listeria monocytogenes infection. Proceedings of the National Academy of Sciences. 2017 May 30:201702077.

Abel zur Wiesch P, Clarelli F, Cohen T. Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies. PLoS Computational Biology. 2017 Jan 6;13(1):e1005321.

Kunkel A, Abel zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins HE, Cohen T. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infectious Diseases. 2016 Jun 13;16(1):282.

Hubbard TP, Chao MC, Abel S, Blondel CJ, Abel zur Wiesch P, Zhou X, Davis BM, Waldor MK. Genetic analysis of Vibrio parahaemolyticus intestinal colonization. Proceedings of the National Academy of Sciences. 2016 May 31;113(22):6283-8.

Cadosch D, Abel zur Wiesch P, Kouyos R, Bonhoeffer S. The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB. PLoS computational biology. 2016 Mar 11;12(3):e1004749.

Salvatore PP, Becerra MC, Abel zur Wiesch P, Hinkley T, Kaur D, Sloutsky A, Cohen T. Fitness costs of drug resistance mutations in multidrug-resistant Mycobacterium tuberculosis: a household-based case-control study. The Journal of infectious diseases. 2015 Jun 19;213(1):149-55.

Abel S, Abel zur Wiesch P, Davis BM, Waldor MK. Analysis of bottlenecks in experimental models of infection. PLoS pathogens. 2015 Jun 11;11(6):e1004823.

Abel zur Wiesch P, Abel S, Gkotzis S, Ocampo P, Engelstaedter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, Cohen T. Antibiotics, pure and simple. Science translational medicine. 2015 May 7(287).

 

Abel zur Wiesch P, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, Cohen T. Classic reaction kinetics can explain complex patterns of antibiotic action. Science translational medicine. 2015 May 13;7(287):287ra73.

Abel S, Abel Zur Wiesch P, Chang HH, Davis BM, Lipsitch M, Waldor MK. Sequence tag-based analysis of microbial population dynamics. Nature methods. 2015 Mar 1;12(3):223-6.

Kouyos RD, Metcalf CJ, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, Arinaminpathy N, Bogich TL, Bonhoeffer S, Brower C, Chi-Johnston G. The path of least resistance: aggressive or moderate treatment?. Proceedings of the Royal Society of London B: Biological Sciences. 2014 Nov 7;281(1794):20140566.

Abel zur Wiesch P, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S. Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLoS pathogens. 2014 Jun 26;10(6):e1004225.

Ocampo PS, Lázár V, Papp B, Arnoldini M, Abel zur Wiesch P, Busa-Fekete R, Fekete G, Pál C, Ackermann M, Bonhoeffer S. Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrobial agents and chemotherapy. 2014 Aug 1;58(8):4573-82.

Abel S, Bucher T, Nicollier M, Hug I, Kaever V, Abel zur Wiesch P, Jenal U. Bi-modal distribution of the second messenger c-di-GMP controls cell fate and asymmetry during the caulobacter cell cycle. PLoS genetics. 2013 Sep 5;9(9):e1003744.

Kouyos RD, Abel zur Wiesch P, Bonhoeffer S. On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community. PLoS pathogens. 2011 Apr 14;7(4):e1001334.

Kouyos RD, Abel zur Wiesch P, Bonhoeffer S. Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards. PLoS computational biology. 2011 Mar 3;7(3):e1001094.

Abel zur Wiesch P, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. Population biological principles of drug-resistance evolution in infectious diseases. The Lancet infectious diseases. 2011 Mar 31;11(3):236-47.

Bonhoeffer S, Abel zur Wiesch P, Kouyos RD. Rotating antibiotics does not minimize selection for resistance. Math Biosci Eng. 2010 Oct 1;7(4):919-22.

Schulz zur Wiesch P, Engelstädter J, Bonhoeffer S. Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrobial agents and chemotherapy. 2010 May 1;54(5):2085-95.

The Abel zur Wiesch Lab

  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey

© 2018

This site was designed with the
.com
website builder. Create your website today.
Start Now